Oncoprotective Effect of Short-Term Hypoxic Training in Model of Ehrlich Ascites Carcinoma in Mice


The search for non-drug therapies to enhance antitumor protection is one of the most urgent tasks of pathophysiology and medicine. We evaluated the impact of a course of interval hypobaric hypoxia (0.306 kg/cm2) on the development of Ehrlich ascites carcinoma (EAC) in mice. In the first series of experiments, the mice were subjected to hypoxic training over 10 days, and in the second series the hypoxic training was provided daily for 3 weeks, except for weekends. The tumor volume was analyzed using a caliper on day 16 (the terminal period). The weight of the mice was measured on day 0, and the final net weight was measured on day 22. The rate of cancer development in mice exposed to hypoxic training within the first 10 days decreased by 58%. Exposure to 3 weeks of hypoxic training showed no significant antitumor effect. Upon completion of the hypoxic training, the rate of tumor development increased, and at the end of the study, no significant differences in survival were found. Further research is needed to determine the optimal antitumor effect and duration of the course of interval hypobaric training.

Keywords: Ehrlich ascites carcinoma (EAC), mice, hypobaric hypoxia, antitumor protection, leukocytes, leukogram

[1] Novikov, V. E., Levchenkova, O. S. and Pozhilova, E. V. (2014). The Role of the Mitochondrial ATPdependent Potassium Channel and its Modules in Cell Adaptation to Hypoxia. Bulletin SGMA, vol. 13, issue 2, pp. 48-54.

[2] Cybulski, C., Nazarali, S. and Narod. S. A. (2014). Multiple Primary Cancers as a Guide to Heritability. International Journal of Cancer. vol. 1135, issue 8, pp. 1756-63.

[3] Bakhtina, L. Y., et al. (2016). Influence of Preliminary Adaptation to Hypoxia on the Development of Epithelial Carcinoma in Rats of Different Genetic Lines. Pathogenesis, vol. 14, issue 1, pp. 62-66.

[4] Inzhevatkin, E. V., et al. (2007). Metabolic Changes in Lymphocytes and Tumor Cells in Mice with Ehrlich Ascites Carcinoma during Tumor Growth. Bulletin of the Russian Academy of Sciences. Biological Series, vol. 3, pp. 376-380.

[5] Lee, A. K., et al. (1999). Increased Oxygen Tensions Influence Subset Composition of the Cellular Immune System in Aged Mice. Cancer-Biother., vol. 9, issue 1, pp. 39-54.

[6] Kalish, S. V., et al. (2015). In Vitro Reprogrammed M1 Macrophages Increase the Lifespan of Mice with Ehrlich Ascites Carcinoma. Pathogenesis, vol. 13, issue 1, pp. 35-42.

[7] de Bock, K., Mazzone, M. and Carmeliet, P. (2001). Antiangiogenic Therapy, Hypoxia, and Metastasis: Risky Liaisons, or Not? Nature Reviews Clinical Oncology, vol. 8, pp. 393-404.

[8] Bykov, V. N., et al. (2017). Prospects for the use of Hypoxic Training for Accelerated Adaptation of Servicemen to Conditions. Marine Medicine, vol. 3, issue 4, pp. 7-15.

[9] Mills, C. D., et al. (2014). Macrophage: SHIP of Immunity. Frontiers in Immunology, vol. 5, p. 620.

[10] Kurochkin, A. A., et al. (2014). Simulation of the Extrudate Production Process Based on a New Technological Solution. Niva Povolzhya, vol. 30, pp. 70-76.

[11] Toropova, Y. G., et al. (2017). Influence of Magnetite Nanoparticles and Colloidal FEMON-SIO2 Particles on the Functional State of the Endothelium after Intravenous Administration to Rats. Russian Journal of Physiology, vol. 103, issue 12, pp. 1416-1424.

[12] Lochhead, P., et al. (2015). Etiologic Field Effect: Reappraisal of the Field Effect Concept in Cancer Predisposition and Progression. Modern Pathology, vol. 28, issue 1, pp. 14-29.

[13] Gromova, O. A., et al. (2018). Adjuvant Therapy with Lignan 7-Hydroxymatairezinol as a Method of Increasing the Oncological Safety of Estrogen Intake. Effective Pharmacotherapy, vol. 13, pp. 14-19.

[14] Flatland B et al. (2010). ASVCP quality assurance guidelines: control of general analytical factors in veterinary laboratories Veterinary Clinical Pathology vol. 3, pp. 264-77

[15] Lisyany, N. I. and Lisyany, A. A. (2018). Neutrophils and Oncogenesis. Clinical Oncology, vol. 8, issue 29, pp. 40-45.

[16] Adamyan, L. V., et al. (2016). Evaluation of the Oncological Safety of Magnerot on the Model of Lung Carcinoma. Consilium Medicum, vol. 18, issue 6, pp. 98-102.

[17] Millar L.J., et al. (2017). Neonatal hypoxia ischaemia: mechanisms, models, and therapeutic challenges Front Cell Neurosci. V. 11, pp. 1-36.

[18] Altland, P. D., Highman, B. and Smith, F. (1963). Immune Response in Rabbits Exposed to High Altitude. International Journal of Infectious Diseases, vol. 113, issue 3, pp. 228-232.

[19] Mantovani, A., Sica, A. and Locati, M. (2006). New Vistas on Macrophage Differentiation and Activation. European Journal of Immunology, vol. 37, issue 1, pp. 14-16.

[20] Berova, M. O. (2007). Immunological Aspects of the Body’s Response to Hypoxia at Different Age Periods. Medical Sciences, vol. 1, pp. 83-91.a